热门资讯> 正文
默克完成对Cidara Therapeutics的现金要约收购
2026-01-07 20:28
- Merck (MRK) has finished its cash tender offer for all outstanding shares of Cidara Therapeutics (CDTX) at a price of $221.50 per Cidara share.
- The deal, announced in November, has a value of $9.2B.
- Merck said after the completion of the merger, it will result in a charge that will increase 2026 research and development expenses by ~$9B or ~$3.65 per share, included in GAAP and non-GAAP results. Also, GAAP and non-GAAP EPS are expected to take a $0.30 per share hit in the first year due to costs associated with advancing CD388 and financing.
- CD388 is an antiviral in phase 3 to prevent influenza infection in individuals at higher risk of influenza complications.
More on Merck
- Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
- Merck: Framework For Success
- Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis
- U.S. measles cases climb to the highest level in over three decades
- Medicare pilot programs aim to reduce prescription drug spend
推荐文章
华盛早报 | 黄金、白银狂飙！特朗普“威胁”引地缘政治风险升温；商业航天爆发！中国新增20万颗卫星申请
港股周报 | 超配中国！高盛称中国股市26年大涨15%至20%；阿里称坚定加大淘宝闪购投入
2026年展望 | 智能驾驶元年或开启！特斯拉Robotaxi引爆赛道，港美股哪些标的值得布局？
美股机会日报 | 重磅大考！“非农+关税裁决”今夜同台亮相；Meta宣布将投资核电厂，OKLO等核电股盘前飙升！
一周财经日历 | 美国12月CPI携手“恐怖数据”来袭；华尔街大行启动Q4财报季，台积电财报或炸场！4只港股新股即将上市
一周IPO | 吃大肉！本周六只新股上市大涨，MINIMAX暴涨109%；BBSB INTL孖展倍数超8900倍，位列史上第三
财报前瞻 | 台积电Q4营收料冲破万亿新台币！大摩喊话绩前买入，2026年股价还能“继续飞”吗？
MiniMax上市首日涨超60%，阿里、米哈游等投资方“躺赢”
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
